BSE Live
Apr 20, 12:39Prev. Close
259.05
Open Price
261.00
Bid Price (Qty.)
263.80 (14)
Offer Price (Qty.)
268.70 (100)
NSE Live
Apr 20, 12:38Prev. Close
259.70
Open Price
261.99
Bid Price (Qty.)
266.50 (91)
Offer Price (Qty.)
267.85 (46)
| Profit & Loss account of Wanbury (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 593.54 | 574.48 | 498.18 | 507.24 | 387.10 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 593.54 | 574.48 | 498.18 | 507.24 | 387.10 | |
| Total Operating Revenues | 599.51 | 575.65 | 499.65 | 511.19 | 392.52 | |
| Other Income | 3.49 | 2.99 | 0.91 | 1.51 | 2.40 | |
| Total Revenue | 603.01 | 578.64 | 500.56 | 512.69 | 394.92 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 277.88 | 289.22 | 257.48 | 304.93 | 213.70 | |
| Purchase Of Stock-In Trade | 15.08 | 17.30 | 15.98 | 20.14 | 10.65 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 1.51 | -3.89 | 29.13 | -24.79 | -7.20 | |
| Employee Benefit Expenses | 104.24 | 86.92 | 81.00 | 74.81 | 64.15 | |
| Finance Costs | 36.95 | 29.18 | 21.39 | 20.61 | 23.07 | |
| Depreciation And Amortisation Expenses | 13.31 | 13.03 | 12.38 | 11.45 | 9.75 | |
| Other Expenses | 124.49 | 116.09 | 92.88 | 100.77 | 93.20 | |
| Total Expenses | 573.46 | 547.86 | 510.25 | 507.93 | 407.33 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 29.55 | 30.78 | -9.69 | 4.76 | -12.41 | |
| Exceptional Items | 0.00 | 0.00 | -0.59 | 76.37 | 0.00 | |
| Profit/Loss Before Tax | 29.55 | 30.78 | -10.29 | 81.13 | -12.41 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 5.86 | 0.00 | 0.00 | 0.00 | 2.27 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -6.84 | 0.38 | 0.11 | -0.35 | -2.07 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | -0.98 | 0.38 | 0.11 | -0.35 | 0.20 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 30.53 | 30.40 | -10.40 | 81.47 | -12.61 | |
| Profit/Loss From Continuing Operations | 30.53 | 30.40 | -10.40 | 81.47 | -12.61 | |
| Profit/Loss For The Period | 30.53 | 30.40 | -10.40 | 81.47 | -12.61 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 9.32 | 9.29 | -3.18 | 25.29 | -5.04 | |
| Diluted EPS (Rs.) | 8.98 | 9.18 | -3.18 | 25.21 | -5.04 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
10.02.2026
Wanbury Standalone December 2025 Net Sales at Rs 162.45 crore, up 21.73% Y-o-Y
24.11.2025
Wanbury Standalone September 2025 Net Sales at Rs 160.06 crore, down 0.7% Y-o-Y
12.08.2025
Wanbury Consolidated June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
05.08.2025
Wanbury Standalone June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
10.02.2026
Wanbury Standalone December 2025 Net Sales at Rs 162.45 crore, up 21.73% Y-o-Y
24.11.2025
Wanbury Standalone September 2025 Net Sales at Rs 160.06 crore, down 0.7% Y-o-Y
12.08.2025
Wanbury Consolidated June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
05.08.2025
Wanbury Standalone June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth